STAT Modulator

AX-202 is a humanized anti-S100A4 monoclonal antibody that neutralizes S100A4. AX-202 blocks downstream profibrotic and proinflammatory effects. AX-202 exerts antifibrotic effects in skin fibrosis. AX-202 induces regression of pre-established skin fibrosis. AX-202 modulates anti-inflammatory and antifibrotic transcriptional pathways. AX-202 inhibits STAT3 phosphorylation. AX-202 induces AMPK and CASQ1 expression. AX-202 modulates SSc-related transcriptional signatures. AX-202 reduces tenascin-C, a DAMP and endogenous TLR4 ligand. AX-202 can be used for the research of systemic sclerosis.

XMU-MP-2 is a selective BRK/PTK6 inhibitor with an IC₅₀ of 5.4 nM. XMU-MP-2 inhibits the proliferation of BRK-positive breast cancer cells and induces apoptosis. XMU-MP-2 is applicable to breast cancer-related research.

Physalin D is isolated from the aerial parts of Physalis angulate. Physalin D displays considerable cytotoxicity against several cancer cell lines, showing IC₅₀ values in the range of d 0.28 to 2.43 microg/mL. Physalin D has the potential for the cancer disease.

TS-IN-5 (Compound 15) is a thymidylate synthase (TS) inhibitor. TS-IN-5 induces Apoptosis by modulating Bax, BCL-2, PI3K, and STAT1 proteins. TS-IN-5 shows antitumor effects against liver, breast and colon cancers.

STAT6 modulator-3 (compound 37) is a STAT6 modulator with an IC₅₀ value less than 300 nM. STAT6 modulator-3 can be used in the research of cancer and inflammatory.

Anticancer agent 259 (Compound 3g) is a Telmisartan (HY-13955)-based cell death modulator, that interfers with the STAT5 signaling pathway, enhances the sensitivity of drug-resistant cells to Imatinib (HY-15463) with SC₅₀ of 1.5 μM.

Zn-DPA-maytansinoid conjugate 1 is a small molecule-based maytansinoid conjugate targeting immune checkpoint. Zn-DPA-maytansinoid conjugate 1 induces lasting regression of tumor growth and rejuvenates tumor microenvironment (TME) to an "inflamed hot tumor" .

anti-TNBC agent-7 (Compound 13c) possesses anticancer activity, serving as a molecular probe to recognize and regulate the signal transduction of the USP21/JAK2/STAT3 axis, exhibiting nanomolar-level cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC).

PF-4942847 is an orally active HSP90 inhibitor with an IC₅₀ of approximately 50 nM. PF-4942847 induces apoptosis in osteosarcoma cells, increases the proportion of cells in the sub-G1 phase and PARP cleavage, reduces the expression of Akt, Erk, MYC, c-MET and STAT-3, and regulates HSP expression. PF-4942847 can be used in studies related to osteosarcoma and HSP90.